Clinical Efficacy of Drug-Eluting Stents Among Hypertensive Patients

doi:N/A

eISSN: 1994-4624 / ISSN: 1813-176x

International Journal of Molecular Medicine and Advance Sciences

2022, Volume 18, Issue 2 : 41-45

Research Article

Clinical Efficacy of Drug-Eluting Stents Among Hypertensive Patients

Arif Mohammad

Sophia Menon

Carlos E. Martinez

Department of Interventional Cardiology National Heart Institute, New Delhi, India

Department of Clinical Pharmacology Indian Institute of Medical Sciences, Bengaluru, India

Received

Aug. 18, 2022

Revised

Sept. 29, 2022

Accepted

Nov. 11, 2022

Published

Dec. 21, 2022

Abstract

Hypertension is an independent predictor of coronary artery disease progression and restenosis following percutaneous coronary intervention (PCI). Drug-eluting stents (DES) have significantly reduced restenosis rates compared to bare-metal stents (BMS), yet their specific clinical benefits among hypertensive patients remain underexplored. This study assesses major adverse cardiac events (MACE), target lesion revascularization (TLR), and stent patency among hypertensive individuals receiving DES. A prospective cohort of 320 hypertensive patients was evaluated over 24 months. Results demonstrated a significant reduction in restenosis (7.4%), lower MACE incidence (11.2%), and improved late lumen loss (0.32 ± 0.08 mm) compared to historical BMS rates. These findings support DES as a superior intervention for hypertensive patients undergoing PCI.

Keywords

Hypertension

Drug-Eluting Stents

PCI

Restenosis

Cardiovascular Intervention

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.

Int. J. Mol. Med. Adv. Sci. open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.

Recommended Articles

Wearable Devices for Chronic Disease Monitoring: Transforming Healthcare Through Continuous Digital Health Surveillance

Sophia M. Richardson,

Ahmed R. Khan,

Priyanka V. Sharma

22-26

Healthcare Disparities and Equity in Medical Services: Challenges, Determinants, and Strategies for Achieving Equitable Healthcare

Katherine Morgan,

Andrew Collins,

Sophia Bennett,

Michael Harrison

27-34